阿普唑仑联合马来酸曲美布汀对功能性胃肠病患者炎症反应、免疫功能及预后的影响分析

Effect analysis of alprazolam combined with trimebutine maleate on inflammation,immune function and prognosis of functional gastrointestinal disease patients

目的分析阿普唑仑与马来酸曲美布汀联合治疗功能性胃肠病的效果及对患者炎症反应、免疫功能和预后的影响。方法88例功能性胃肠病患者,依据随机数字表法分为对照组和研究组,每组44例。对照组以马来酸曲美布汀实施治疗,研究组以阿普唑仑与马来酸曲美布汀联合治疗。对比两组的临床疗效、炎症因子[白细胞介素-12(IL-12)、白细胞介素-10(IL-10)、白细胞介素-8(IL-8)]、免疫功能(CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+))及匹兹堡睡眠质量指数(PSQI)评分。结果研究组总有效率97.73%高于对照组的81.82%(P<0.05)。治疗前,两组患者的IL-12、IL-10、IL-8水平比较无差异(P>0.05);治疗后,研究组IL-12、IL-8水平相比对照组较低,IL-10水平相比对照组较高(P<0.05)。治疗前,两组患者CD3^(+)、CD4^(+)、CD8^(+)、CD4^(+)/CD8^(+)比较无差异(P>0.05);治疗后,研究组CD8^(+)(29.43±5.26)%相比对照组的(34.67±5.09)%较低,CD3^(+)(80.49±5.62)%、CD4^(+)(49.88±5.71)%、CD4^(+)/CD8^(+)(1.92±0.37)相比对照组的(73.49±7.51)%、(43.29±4.82)%、(1.61±0.25)较高(P<0.05)。治疗前,两组PSQI评分比较无差异(P>0.05);治疗后,研究组PSQI评分(11.06±1.37)分相比对照组的(15.12±1.45)分较低(P<0.05)。结论阿普唑仑与马来酸曲美布汀联合治疗功能性胃肠病的效果较好,可有效改善患者的炎症反应及免疫功能,值得临床推广。

Objective To analyze the effect of alprazolam combined with trimebutine maleate on functional gastrointestinal disease,and its influence on inflammation,immune function and prognosis of patients.Methods 88 patients with functional gastrointestinal disease were divided into a control group and a study group according to random number table method,with 44 cases in each group.The control group was treated with trimebutine maleate,and the study group was treated with alprazolam combined with trimebutine maleate.Comparison was made on clinical efficacy,inflammatory factors[interleukin-12(IL-12),interleukin-10(IL-10),interleukin-8(IL-8)],immune function(CD3^(+),CD4^(+),CD8^(+),CD4^(+)/CD8^(+))and Pittsburgh Sleep Quality Index(PSQI)scores between the two groups.Results The total effective rate of the study group was 97.73%,which was higher than the control group's 81.82%(P<0.05).Before treatment,there were no differences in IL-12,IL-10 and IL-8 levels between the two groups(P>0.05).After treatment,the levels of IL-12 and IL-8 in the study group were lower than those in the control group,and the level of IL-10 was higher than that in the control group(P<0.05).Before treatment,there was no differences in CD3^(+),CD4^(+),CD8^(+)and CD4^(+)/CD8^(+)between the two groups(P>0.05).After treatment,the study group had lower CD8^(+)of(29.43±5.26)%than(34.67±5.09)%in the control group;the study group had CD3^(+)of(80.49±5.62)%,CD4^(+)of(49.88±5.71)%and CD4^(+)/CD8^(+)of(1.92±0.37),which were higher than(73.49±7.51)%,(43.29±4.82)%and(1.61±0.25)in the control group(P<0.05).Before treatment,there was no differences in PSQI scores between the two groups(P>0.05).After treatment,the study group had lower PSQI score of(11.06±1.37)points than(15.12±1.45)points in the control group(P<0.05).Conclusion The combination of alprazolam and trimebutine maleate in the treatment of functional gastrointestinal disease has a good effect,which can effectively improve the inflammation and immune function of patients,and is worthy of clinical promotion.